Loss of SEMA3A was also associated with higher-grade (grade III) ductal carcinomas and poor survival in a panel of 2878 breast cancer patients [13], associating the loss of SEMA3A with aggressive breast cancer. This evidence concerns the gene SEMA3A and breast carcinoma.